ARTICLE | Company News

One year later, Agenus hits home run with Incyte deal

January 9, 2015 8:00 AM UTC

Shares of Agenus Inc. (NASDAQ:AGEN) jumped $1.18 (29%) to $5.30 on Friday, adding $82.6 million in market cap, after the company entered a five-year collaboration with Incyte Corp. (NASDAQ:INCY) to develop and commercialize novel immuno-therapeutics in hematology and oncology using Agenus' Retrocyte Display antibody discovery platform.

Agenus got the Retrocyte platform through its 4-Antibody AG acquisition last year for $10 million in cash and contingent value payments that the company said could exceed $40 million (see BioCentury, Jan. 27, 2014). ...